Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Otorhinolaryngology

Free Subscription Articles published in Radiother Oncol Retrieve available abstracts of 219 articles: HTML format

Single Articles

June 2024
1. LIU YC, Zhang X, Yang HN, Zhang L, et al
   Proposals for the delineation of neck clinical target volume for definitive Radiation therapy in patients with oral/ oropharyngeal squamous cell cancer based on lymph node distribution.
   Radiother Oncol. 2024;195:110225.
   PubMed     Abstract available
   
   
   May 2024
2. ZHANG WW, Guo R
   Response to "Comments on 'Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study'".
   Radiother Oncol. 2024 May 11:110327. doi: 10.1016/j.radonc.2024.110327.
   PubMed    
   
   
   
3. ZHAN ZJ, Huang HY, Xiao YH, Zhao YP, et al
   Anxiety and depression in nasopharyngeal carcinoma patients and network analysis to identify central symptoms: A cross-sectional study from a high-incidence area.
   Radiother Oncol. 2024 May 10:110324. doi: 10.1016/j.radonc.2024.110324.
   PubMed     Abstract available
   
   
   
4. SHEN M, Lin X, Yang C, Zhou Z, et al
   Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma.
   Radiother Oncol. 2024 May 9:110323. doi: 10.1016/j.radonc.2024.110323.
   PubMed     Abstract available
   
   
   
5. SMITS HJG, Raaijmakers CPJ, de Ridder M, Gouw ZAR, et al
   Improved delineation with diffusion weighted imaging for laryngeal and hypopharyngeal tumors validated with pathology.
   Radiother Oncol. 2024;194:110182.
   PubMed     Abstract available
   
   
   April 2024
6. XU L, Liu S, Yang Y, Shu L, et al
   LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/STIM1 axis.
   Radiother Oncol. 2024;196:110310.
   PubMed     Abstract available
   
   
   
7. LIU Y, Ma J, Zeng XY, Zuo ZC, et al
   Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study.
   Radiother Oncol. 2024;196:110311.
   PubMed     Abstract available
   
   
   
8. STARUCH M, Speth MM, Neyer P, Riesterer O, et al
   Radiation-associated changes in saliva composition of head and neck cancer patients: A systematic review.
   Radiother Oncol. 2024 Apr 20:110279. doi: 10.1016/j.radonc.2024.110279.
   PubMed     Abstract available
   
   
   
9. SELENGE BEDUK ESEN C, Nur Can G, Akkus Yildirim B
   Comments on "Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study".
   Radiother Oncol. 2024 Apr 20:110292. doi: 10.1016/j.radonc.2024.110292.
   PubMed    
   
   
   
10. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
    Risk factors associated with the development of osteoradionecrosis (ORN) in Head and Neck cancer patients in Ireland: A 10-year retrospective review.
    Radiother Oncol. 2024 Apr 17:110286. doi: 10.1016/j.radonc.2024.110286.
    PubMed     Abstract available
    
    
    
11. ZHENG Z, Shen Y, Su J, Ji X, et al
    Assessing radiation-induced carotid artery injury using ultrasound in patients with head and neck cancer.
    Radiother Oncol. 2024 Apr 17:110285. doi: 10.1016/j.radonc.2024.110285.
    PubMed     Abstract available
    
    
    
12. CHEN AM, Harris JP, Nabar R, Tjoa T, et al
    Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
    Radiother Oncol. 2024 Apr 16:110278. doi: 10.1016/j.radonc.2024.110278.
    PubMed     Abstract available
    
    
    
13. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
    A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
    Radiother Oncol. 2024 Apr 16:110281. doi: 10.1016/j.radonc.2024.110281.
    PubMed     Abstract available
    
    
    
14. SHUANG H, Feng J, Caineng C, Qifeng J, et al
    Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study.
    Radiother Oncol. 2024 Apr 5:110265. doi: 10.1016/j.radonc.2024.110265.
    PubMed     Abstract available
    
    
    
15. CHOW JCH, Lee J, Lai MMP, Li S, et al
    Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional study.
    Radiother Oncol. 2024;193:110143.
    PubMed     Abstract available
    
    
    March 2024
16. DONG J, Ng WT, Wong CHL, Li JS, et al
    Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis.
    Radiother Oncol. 2024 Mar 25:110258. doi: 10.1016/j.radonc.2024.110258.
    PubMed     Abstract available
    
    
    
17. HUYNH TM, Falk RS, Hellebust TP, Dale E, et al
    Chronic fatigue in long-term survivors of head and neck cancer treated with radiotherapy.
    Radiother Oncol. 2024;195:110231.
    PubMed     Abstract available
    
    
    
18. BERTHOLET J, Mackeprang PH, Loebner HA, Mueller S, et al
    Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
    Radiother Oncol. 2024 Mar 19:110237. doi: 10.1016/j.radonc.2024.110237.
    PubMed     Abstract available
    
    
    
19. BOON CS, Ramkumar S, Boon IS
    Proton beam radiotherapy head and neck cancer study design and endpoints.
    Radiother Oncol. 2024 Mar 16:110234. doi: 10.1016/j.radonc.2024.110234.
    PubMed    
    
    
    
20. KOUTROUMPAKIS E, Mohamed ASR, Chaftari P, Rosenthal DI, et al
    Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study.
    Radiother Oncol. 2024 Mar 9:110220. doi: 10.1016/j.radonc.2024.110220.
    PubMed     Abstract available
    
    
    
21. CHOW JCH, Ho JCS, Man Cheung K, Johnson D, et al
    Neurological complications of modern radiotherapy for head and neck cancer.
    Radiother Oncol. 2024 Mar 2:110200. doi: 10.1016/j.radonc.2024.110200.
    PubMed     Abstract available
    
    
    
22. CARSUZAA F, Chary E, Thariat J, Dufour X, et al
    Obstructive sleep apnea syndrome: A frequent and difficult-to-detect complication of radiotherapy for oropharyngeal cancers.
    Radiother Oncol. 2024;192:110109.
    PubMed     Abstract available
    
    
    
23. ZHANG WW, Lin JY, Wang GY, Huang CL, et al
    Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Radiother Oncol. 2024;194:110189.
    PubMed     Abstract available
    
    
    February 2024
24. POPULAIRE P, Defraene G, Haustermans K
    Letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
    Radiother Oncol. 2024 Feb 28:110175. doi: 10.1016/j.radonc.2024.110175.
    PubMed    
    
    
    
25. KOTO M, Ikawa H, Inaniwa T, Imai R, et al
    Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers.
    Radiother Oncol. 2024;194:110180.
    PubMed     Abstract available
    
    
    
26. BERBEE M, Muijs CT, Schuit E
    Response to letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
    Radiother Oncol. 2024 Feb 17:110176. doi: 10.1016/j.radonc.2024.110176.
    PubMed    
    
    
    
27. FIORINO C, Palumbo D, Mori M, Palazzo G, et al
    Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial.
    Radiother Oncol. 2024;194:110160.
    PubMed     Abstract available
    
    
    
28. WANG X, Huang N, Yip PL, Wang J, et al
    The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-word study with a large population.
    Radiother Oncol. 2024;194:110154.
    PubMed     Abstract available
    
    
    
29. HORSHOLT KRISTENSEN M, Kristina Sorensen M, Tramm T, Alsner J, et al
    Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - a DAHANCA 19 study.
    Radiother Oncol. 2024 Feb 8:110149. doi: 10.1016/j.radonc.2024.110149.
    PubMed     Abstract available
    
    
    
30. PERRIER L, Balusson F, Morelle M, Castelli J, et al
    Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
    Radiother Oncol. 2024;193:110116.
    PubMed     Abstract available
    
    
    January 2024
31. FRANK MH, van Dijk BAC, Schoonbeek RC, Zindler J, et al
    Differences in the association of time to treatment initiation and survival according to various head and neck cancer sites in a nationwide cohort.
    Radiother Oncol. 2024 Jan 21:110107. doi: 10.1016/j.radonc.2024.110107.
    PubMed     Abstract available
    
    
    
32. BLITZER GC, Paz C, Glassey A, Ganz OR, et al
    Functionality of Bone Marrow Mesenchymal Stromal Cells Derived from Head and Neck Cancer Patients - A FDA-IND Enabling Study Regarding MSC-based Treatments for Radiation-Induced Xerostomia.
    Radiother Oncol. 2024 Jan 13:110093. doi: 10.1016/j.radonc.2024.110093.
    PubMed     Abstract available
    
    
    
33. PIERIK AS, Poell JB, Brink A, Stigter-van Walsum M, et al
    Intratumor genetic heterogeneity and head and neck cancer relapse.
    Radiother Oncol. 2024 Jan 5:110087. doi: 10.1016/j.radonc.2024.110087.
    PubMed     Abstract available
    
    
    
34. WANG F, Zhou L, Zhang LJ, Xie CB, et al
    Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: a propensity score-matched cohort study.
    Radiother Oncol. 2024 Jan 5:110081. doi: 10.1016/j.radonc.2024.110081.
    PubMed     Abstract available
    
    
    
35. GUO Q, Lu T, Huang W, Xu H, et al
    Selectively sparing of the supraclavicular area during intensity-modulated radiotherapy in nasopharyngeal carcinoma: A double-center observation study.
    Radiother Oncol. 2024 Jan 4:110086. doi: 10.1016/j.radonc.2024.110086.
    PubMed     Abstract available
    
    
    
36. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
    Response to the letter-to-the-editor "Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
    Radiother Oncol. 2024;190:110036.
    PubMed    
    
    
    
37. SOMAY E, Yilmaz B, Topkan E
    Comments on "Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
    Radiother Oncol. 2024;190:110035.
    PubMed    
    
    
    
38. ZHU Y, Cheng J, Li Y, Pan D, et al
    Progression of cognitive dysfunction in NPC survivors with radiation-induced brain necrosis: A prospective cohort.
    Radiother Oncol. 2024;190:110033.
    PubMed     Abstract available
    
    
    December 2023
39. MURDAUGH DL, Milner D, Cardenas CE, Heinzman KA, et al
    Volumetric Brain Assessment of Long-Term Head and Neck Cancer Survivors.
    Radiother Oncol. 2023 Dec 22:110068. doi: 10.1016/j.radonc.2023.110068.
    PubMed     Abstract available
    
    
    
40. LIN CY, Chang CL, Lin KC, Chen WM, et al
    Statin Use Reduces Radiation-Induced Stroke Risk in Advanced Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 Dec 22:110067. doi: 10.1016/j.radonc.2023.110067.
    PubMed     Abstract available
    
    
    
41. YU-CHEN, Luo MJ, Liu RP, Jin J, et al
    Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Dec 20:110051. doi: 10.1016/j.radonc.2023.110051.
    PubMed     Abstract available
    
    
    
42. AI QYH, King AD, Yuan H, Vardhanabhuti V, et al
    Radiologic extranodal extension for nodal staging in nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Dec 13:110050. doi: 10.1016/j.radonc.2023.110050.
    PubMed     Abstract available
    
    
    
43. BIRD D, Speight R, Andersson S, Wingqvist J, et al
    Deep learning MRI-only synthetic-CT generation for pelvis, brain and head and neck cancers.
    Radiother Oncol. 2023 Dec 12:110052. doi: 10.1016/j.radonc.2023.110052.
    PubMed     Abstract available
    
    
    
44. HABRICH J, Boeke S, Fritz V, Koerner E, et al
    Reproducibility of diffusion-weighted magnetic resonance imaging in head and neck cancer assessed on a 1.5 T MR-Linac and comparison to parallel measurements on a 3 T diagnostic scanner.
    Radiother Oncol. 2023 Dec 7:110046. doi: 10.1016/j.radonc.2023.110046.
    PubMed     Abstract available
    
    
    
45. MARIA HUYNH TT, Dale E, Sorum Falk R, Paulsen Hellebust T, et al
    Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters.
    Radiother Oncol. 2023 Dec 5:110044. doi: 10.1016/j.radonc.2023.110044.
    PubMed     Abstract available
    
    
    
46. HOU Z, Guo Y, Shen X, Dong B, et al
    Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study.
    Radiother Oncol. 2023;189:109937.
    PubMed     Abstract available
    
    
    November 2023
47. MENG Z, Li P, Yang D, Huang H, et al
    The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.
    Radiother Oncol. 2023 Nov 24:110027. doi: 10.1016/j.radonc.2023.110027.
    PubMed     Abstract available
    
    
    
48. SOMAY E, Topkan E, Selek U
    Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Nov 24:110025. doi: 10.1016/j.radonc.2023.110025.
    PubMed    
    
    
    
49. BUURMAN DJM, Speksnijder CM, Granzier ME, Timmer VCML, et al
    Response to: Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Nov 24:110026. doi: 10.1016/j.radonc.2023.110026.
    PubMed    
    
    
    
50. DELERUE C, Pasquier D, Bogart E, Mirabel X, et al
    Stereotactic reirradiation in the treatment of head and neck cancers: A retrospective study on the long-term experience of the Oscar Lambret Center.
    Radiother Oncol. 2023;190:110029.
    PubMed     Abstract available
    
    
    
51. HUANG CL, Wang GY, Lou JH, Chen L, et al
    Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up.
    Radiother Oncol. 2023;190:110032.
    PubMed     Abstract available
    
    
    
52. BERBEE M, Muijs CT, Voncken FEM, Wee LS, et al
    External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts.
    Radiother Oncol. 2023 Nov 8:109979. doi: 10.1016/j.radonc.2023.109979.
    PubMed     Abstract available
    
    
    
53. HR M, P P, L H, Ds M, et al
    PROton versus photon Therapy for Esophageal Cancer - a Trimodality strategy (PROTECT) NCT050555648.
    Radiother Oncol. 2023 Nov 5:109980. doi: 10.1016/j.radonc.2023.109980.
    PubMed    
    
    
    
54. CHEN L, Li J, Li K, Hu J, et al
    Evaluation and Analysis of Risk Factors of Hearing Impairment for Nasopharyngeal Carcinoma treated using Intensity-Modulated Radiotherapy.
    Radiother Oncol. 2023 Nov 3:109985. doi: 10.1016/j.radonc.2023.109985.
    PubMed     Abstract available
    
    
    
55. KIM K, Oh D, Myoung Noh J, Won Min Y, et al
    Outcomes Following Hypofractionated Radiation Therapy Alone for Surgically Unfit Early Esophageal Squamous Cell Carcinoma Patients; A Retrospective Single Center Analysis.
    Radiother Oncol. 2023 Nov 3:109982. doi: 10.1016/j.radonc.2023.109982.
    PubMed     Abstract available
    
    
    October 2023
56. HE YQ, Wang TM, Yang DW, Xue WQ, et al
    A comprehensive predictive model for radiation-induced brain injury in risk stratification and personalized radiotherapy of nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Oct 30:109974. doi: 10.1016/j.radonc.2023.109974.
    PubMed     Abstract available
    
    
    
57. AMSTUTZ F, Krcek R, Bachtiary B, Weber DC, et al
    Treatment planning comparison for head and neck cancer between photon, proton, and combined proton-photon therapy - from a fixed beam line to an arc.
    Radiother Oncol. 2023 Oct 30:109973. doi: 10.1016/j.radonc.2023.109973.
    PubMed     Abstract available
    
    
    
58. FRIBORG J, Jensen K, Eriksen JG, Samsoe E, et al
    Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer.
    Radiother Oncol. 2023 Oct 21:109958. doi: 10.1016/j.radonc.2023.109958.
    PubMed     Abstract available
    
    
    
59. CHEN AM
    Management of Unknown Primary Head and Neck Cancer with Radiation Therapy in the Era of Human Papillomavirus (HPV): No Longer Cutting Down the Tree to Get an Apple.
    Radiother Oncol. 2023 Oct 14:109952. doi: 10.1016/j.radonc.2023.109952.
    PubMed     Abstract available
    
    
    
60. GAI X, Su L, Huang S, Zeng J, et al
    Correlation between hippocampal radiation doses and psychological condition for patients with stage T1-2 nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Oct 7:109942. doi: 10.1016/j.radonc.2023.109942.
    PubMed     Abstract available
    
    
    
61. LI S, Zhang W, Liang B, Huang W, et al
    A Rulefit-Based Prognostic Analysis Using Structured MRI Report to Select Potential Beneficiaries from Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Dual-Centre Study.
    Radiother Oncol. 2023 Oct 7:109943. doi: 10.1016/j.radonc.2023.109943.
    PubMed     Abstract available
    
    
    
62. LIN CH, Yan JL, Yap WK, Kang CJ, et al
    Prognostic Value of Interim CT-based Peritumoral and Intratumoral Radiomics in Laryngeal and Hypopharyngeal Cancer Patients Undergoing Definitive Radiotherapy.
    Radiother Oncol. 2023 Oct 6:109938. doi: 10.1016/j.radonc.2023.109938.
    PubMed     Abstract available
    
    
    
63. SUN XS, Wang JW, Han F, Zou RH, et al
    Prognostic value of metastatic cervical lymph node stiffness in nasopharyngeal carcinoma: A prospective cohort study.
    Radiother Oncol. 2023 Oct 6:109939. doi: 10.1016/j.radonc.2023.109939.
    PubMed     Abstract available
    
    
    September 2023
64. YEONG SONG J, Sung Ho M, Suh YG, Kim JH, et al
    Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: a multicenter retrospective study (KROG 21-10).
    Radiother Oncol. 2023 Sep 30:109936. doi: 10.1016/j.radonc.2023.109936.
    PubMed     Abstract available
    
    
    
65. BOLLEN H, Gulyban A, Nuyts S
    Impact of consensus guidelines on delineation of primary tumor Clinical Target Volume (CTVp) for head and neck cancer: results of a national review project.
    Radiother Oncol. 2023 Sep 20:109915. doi: 10.1016/j.radonc.2023.109915.
    PubMed     Abstract available
    
    
    
66. LIU S, Zou Y, Zhong M, Li T, et al
    Prognostic Significance of MRI-Defined Sarcopenia in Patients with Nasopharyngeal Carcinoma: A Propensity Score Matched Analysis of Real-World Data.
    Radiother Oncol. 2023 Sep 5:109904. doi: 10.1016/j.radonc.2023.109904.
    PubMed     Abstract available
    
    
    
67. YAN W, Liu T, He M, Yi J, et al
    Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.
    Radiother Oncol. 2023 Sep 5:109903. doi: 10.1016/j.radonc.2023.109903.
    PubMed     Abstract available
    
    
    
68. ADRIAN G, Forslund O, Pedersen L, Sjovall J, et al
    Circulating tumour HPV16 DNA quantification - A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy.
    Radiother Oncol. 2023;186:109773.
    PubMed     Abstract available
    
    
    
69. SIJTSEMA ND, Verduijn GM, Nasserinejad K, van Norden Y, et al
    Development of a local dose-response relationship for osteoradionecrosis within the mandible.
    Radiother Oncol. 2023;186:109736.
    PubMed     Abstract available
    
    
    
70. LI D, Yang LN, Lin JY, Wu YZ, et al
    Eosinophil Dynamics During Chemo-Radiotherapy Correlate to Clinical Outcome in Stage ?-?a Nasopharyngeal Carcinoma Patients: Results from A Large Cohort Study.
    Radiother Oncol. 2023 Sep 1:109900. doi: 10.1016/j.radonc.2023.109900.
    PubMed     Abstract available
    
    
    August 2023
71. OZER O, Shafi H, O'Reilly D, Loiseau C, et al
    Need for standardization in the use of structures in the intensity-modulated radiation therapy planning of head and neck cancers, a GORTEC study.
    Radiother Oncol. 2023 Aug 31:109895. doi: 10.1016/j.radonc.2023.109895.
    PubMed     Abstract available
    
    
    
72. DING X, Cui X, Cui X, Wang S, et al
    Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: a meta-analysis.
    Radiother Oncol. 2023 Aug 23:109860. doi: 10.1016/j.radonc.2023.109860.
    PubMed     Abstract available
    
    
    
73. ROESCH J, Ruhle A, Nicolay NH, Hecht M, et al
    Reply to the comment on "Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis'' by Kahvecioglu et al.
    Radiother Oncol. 2023 Aug 22:109866. doi: 10.1016/j.radonc.2023.109866.
    PubMed    
    
    
    
74. IYIZOBA-EBOZUE Z, Prestwich R, Brown S, Hall E, et al
    Neurocognitive function following (chemo)radiotherapy for nasopharyngeal cancer and other head and neck cancers: a systematic review.
    Radiother Oncol. 2023 Aug 22:109863. doi: 10.1016/j.radonc.2023.109863.
    PubMed     Abstract available
    
    
    
75. KATSUTA T, Murakami Y, Kawahara D, Miyoshi S, et al
    Novel Simulation for Dosimetry Impact of Diaphragm Respiratory Motion in Four-Dimensional Volumetric Modulated Arc Therapy for Esophageal Cancer.
    Radiother Oncol. 2023 Aug 8:109849. doi: 10.1016/j.radonc.2023.109849.
    PubMed     Abstract available
    
    
    
76. BUURMAN DJM, Speksnijder CM, Granzier ME, C M L Timmer V, et al
    The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Aug 3:109847. doi: 10.1016/j.radonc.2023.109847.
    PubMed     Abstract available
    
    
    
77. KOTEVSKI DP, Vajdic CM, Field M, Smee RI, et al
    Inter-hospital variation in data collection, radiotherapy treatment, and survival in patients with head and neck cancer: a multisite study.
    Radiother Oncol. 2023 Aug 3:109843. doi: 10.1016/j.radonc.2023.109843.
    PubMed     Abstract available
    
    
    
78. DIAS GOMES DA SILVA N, Sergio da Silva Santos P, Carolina Magalhaes A, Afonso Rabelo Buzalaf M, et al
    Antibacterial, antibiofilm and anticaries effect of BioXtra(R) mouthrinse for head and neck cancer (HNC) patients under a microcosm biofilm model.
    Radiother Oncol. 2023 Aug 3:109846. doi: 10.1016/j.radonc.2023.109846.
    PubMed     Abstract available
    
    
    July 2023
79. LIU J, Zhang B, Su Y, Qin G, et al
    Hypofractionated Radiotherapy compared with Conventionally Fractionated Radiotherapy to treat Initial Distant Metastases in Nasopharyngeal Carcinoma: A Multicenter, prospective, randomized, Phase II Trial.
    Radiother Oncol. 2023 Jul 20:109815. doi: 10.1016/j.radonc.2023.109815.
    PubMed     Abstract available
    
    
    
80. HANSEN CR, Jensen K, Smulders B, Holm AIS, et al
    Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35.
    Radiother Oncol. 2023 Jul 19:109812. doi: 10.1016/j.radonc.2023.109812.
    PubMed     Abstract available
    
    
    
81. KAHVECIOGLU A, Yuce Sari S, Yazici G
    Comments on ''Dose-escalated Re-irradiation Improves Outcome in Locally Recurrent Head and Neck Cancer - Results of a Large Multicenter Analysis''.
    Radiother Oncol. 2023 Jul 17:109809. doi: 10.1016/j.radonc.2023.109809.
    PubMed    
    
    
    
82. LIN C, Lu N, Liang JL, Guo J, et al
    Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Jul 7:109802. doi: 10.1016/j.radonc.2023.109802.
    PubMed     Abstract available
    
    
    
83. CONTI A
    In regard to: "Dosimetric predictive factors for facial nerve paralysis after Cyberknife stereotactic radiotherapy for vestibular schwannomas: A single institution experience of 88 patients".
    Radiother Oncol. 2023 Jul 6:109796. doi: 10.1016/j.radonc.2023.109796.
    PubMed    
    
    
    
84. GEHIN W, Lassalle B, Salleron J, Anxionnat R, et al
    Response to the letter-to-the-editor "In regard to: Dosimetric predictive factors for facial nerve paralysis after Cyberknife stereotactic radiotherapy for vestibular schwannomas: A single institution experience of 88 patients".
    Radiother Oncol. 2023 Jul 6:109797. doi: 10.1016/j.radonc.2023.109797.
    PubMed    
    
    
    
85. WEISS Y, Chin L, Younas E, Guo K, et al
    Cine MRI-based Analysis of Intrafractional Motion in Radiation Treatment Planning of Head and Neck Cancer Patients.
    Radiother Oncol. 2023 Jul 4:109790. doi: 10.1016/j.radonc.2023.109790.
    PubMed     Abstract available
    
    
    
86. LIN P, Holloway L, Min M, Lee M, et al
    Prognostic and predictive values of baseline and mid-treatment FDG-PET in oropharyngeal carcinoma treated with primary definitive (chemo)radiation and impact of HPV status: Review of current literature and emerging roles.
    Radiother Oncol. 2023;184:109686.
    PubMed     Abstract available
    
    
    
87. DE JONG BA, Korevaar EW, Maring A, Werkman CI, et al
    Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model based clinic.
    Radiother Oncol. 2023;184:109670.
    PubMed     Abstract available
    
    
    
88. ZHOU J, Wu J, Wu G, Huang J, et al
    TBX18 knockdown sensitizes esophageal squamous cell carcinoma to radiotherapy by blocking the CHN1/RhoA axis.
    Radiother Oncol. 2023 Jul 1:109788. doi: 10.1016/j.radonc.2023.109788.
    PubMed     Abstract available
    
    
    June 2023
89. KJEMS J, Elisabet Hakansson K, Andrup Kristensen C, Grau Eriksen J, et al
    The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas.
    Radiother Oncol. 2023 Jun 27:109771. doi: 10.1016/j.radonc.2023.109771.
    PubMed     Abstract available
    
    
    
90. LIN X, Guo Z, Lin S, Qiu Y, et al
    Transcriptional expression of radiation-induced early cortical morphological alterations and its association with radiation necrosis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Jun 27:109770. doi: 10.1016/j.radonc.2023.109770.
    PubMed     Abstract available
    
    
    
91. GAN Y, Langendijk JA, van der Schaaf A, van den Bosch L, et al
    An efficient strategy to select head and neck cancer patients for adaptive radiotherapy.
    Radiother Oncol. 2023 Jun 21:109763. doi: 10.1016/j.radonc.2023.109763.
    PubMed     Abstract available
    
    
    
92. YANG Q, Xia L, Feng LF, Gong WJ, et al
    Multi-trajectories of health-related quality of life and their associated factors in patients with nasopharyngeal carcinoma: A longitudinal study.
    Radiother Oncol. 2023 Jun 12:109743. doi: 10.1016/j.radonc.2023.109743.
    PubMed     Abstract available
    
    
    
93. ROJO-SANTIAGO J, Korevaar E, Perko Z, Both S, et al
    PTV-based VMAT vs. robust IMPT for Head-and-Neck Cancer: A probabilistic uncertainty analysis of clinical plan evaluation with the Dutch model-based selection.
    Radiother Oncol. 2023 Jun 8:109729. doi: 10.1016/j.radonc.2023.109729.
    PubMed    
    
    
    
94. CAMPO F, Iocca O, De Virgilio A, Mazzola F, et al
    Treatment of oropharyngeal squamous cell carcinoma: Is swallowing quality better after TORS or RT?
    Radiother Oncol. 2023;183:109547.
    PubMed     Abstract available
    
    
    May 2023
95. KONG FF, Pan GS, Du CR, Ni MS, et al
    Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: a recursive partitioning risk stratification analysis.
    Radiother Oncol. 2023 May 25:109721. doi: 10.1016/j.radonc.2023.109721.
    PubMed     Abstract available
    
    
    
96. MCDONALD BA, Salzillo T, Mulder S, Ahmed S, et al
    Prospective Evaluation of In Vivo and Phantom Repeatability and Reproducibility of Diffusion-Weighted MRI Sequences on 1.5T MRI-Linear Accelerator (MR-Linac) and MR Simulator Devices for Head and Neck Cancers.
    Radiother Oncol. 2023 May 19:109717. doi: 10.1016/j.radonc.2023.109717.
    PubMed     Abstract available
    
    
    
97. LU T, Xu H, Huang W, Zong J, et al
    Constructing an Individualized Surveillance Framework for Nasopharyngeal Carcinoma Based on a Dynamic Risk-adapted Approach.
    Radiother Oncol. 2023 May 17:109716. doi: 10.1016/j.radonc.2023.109716.
    PubMed     Abstract available
    
    
    
98. MORAL NAKAMURA D, da Graca Pinto H, Baena Elchin C, Thomazotti Berard L, et al
    Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2023 May 17:109715. doi: 10.1016/j.radonc.2023.109715.
    PubMed     Abstract available
    
    
    
99. LU J, Qin Z, Li N, Ma J, et al
    High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2023 May 9:109700. doi: 10.1016/j.radonc.2023.109700.
    PubMed     Abstract available
    
    
    
100. FENG ZONG J, Lin PJ, Tsou HH, Guo Q, et al
     Comparison the Acute Toxicity of Two Different Induction Chemotherapy Schedules with Cisplatin and Fluorouracil in Nasopharyngeal Carcinoma Patients.
     Radiother Oncol. 2023 May 9:109699. doi: 10.1016/j.radonc.2023.109699.
     PubMed     Abstract available
     
     
     April 2023
101. ZHAO DW, Teng F, Meng LL, Fan WJ, et al
     Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.
     Radiother Oncol. 2023 Apr 27:109683. doi: 10.1016/j.radonc.2023.109683.
     PubMed     Abstract available
     
     
     
102. PAN Z, Men K, Liang B, Song Z, et al
     A subregion-based prediction model for local-regional recurrence risk in head and neck squamous cell carcinoma.
     Radiother Oncol. 2023 Apr 27:109684. doi: 10.1016/j.radonc.2023.109684.
     PubMed     Abstract available
     
     
     
103. ZHAO W, Ke S, Cai X, Zuo Z, et al
     Radiotherapy plus camrelizumaband irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
     Radiother Oncol. 2023 Apr 25:109679. doi: 10.1016/j.radonc.2023.109679.
     PubMed     Abstract available
     
     
     
104. A C FIAGAN Y, Bossuyt E, Nevens D, Machiels M, et al
     The use of in-vivo dosimetry to identify head and neck cancer patients needing adaptive radiotherapy.
     Radiother Oncol. 2023 Apr 19:109676. doi: 10.1016/j.radonc.2023.109676.
     PubMed     Abstract available
     
     
     March 2023
105. BOLOGNA M, Corino V, Cavalieri S, Calareso G, et al
     Prognostic radiomic signature for head and neck cancer: development and validation on a multi-centric MRI dataset.
     Radiother Oncol. 2023 Mar 31:109638. doi: 10.1016/j.radonc.2023.109638.
     PubMed     Abstract available
     
     
     
106. MENECEUR S, Lock S, Gudziol V, Hering S, et al
     Corrigendum to "Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens" [Radiother. Oncol. 137 (2019) 24-31].
     Radiother Oncol. 2023;183:109619.
     PubMed    
     
     
     
107. S R MOHAMED A, Abusaif A, He R, Wahid K, et al
     Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualification study.
     Radiother Oncol. 2023 Mar 27:109641. doi: 10.1016/j.radonc.2023.109641.
     PubMed     Abstract available
     
     
     
108. LU ZJ, Liu T, Lin JY, Pei ST, et al
     Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma.
     Radiother Oncol. 2023 Mar 22:109635. doi: 10.1016/j.radonc.2023.109635.
     PubMed     Abstract available
     
     
     
109. ALY F, Ronn Hansen C, Al Mouiee D, Sundaresan P, et al
     Outcome prediction models incorporating clinical variables for Head and Neck Squamous cell Carcinoma: a systematic review of methodological conduct and risk of bias.
     Radiother Oncol. 2023 Mar 17:109629. doi: 10.1016/j.radonc.2023.109629.
     PubMed    
     
     
     
110. DUBEC MJ, Buckley DL, Berks M, Clough A, et al
     First-in-Human Technique Translation of Oxygen-Enhanced MRI to an MR Linac System in Patients with Head and Neck Cancer.
     Radiother Oncol. 2023 Mar 2:109592. doi: 10.1016/j.radonc.2023.109592.
     PubMed     Abstract available
     
     
     
111. WU Z, Qi B, Lin FF, Zhang L, et al
     Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.
     Radiother Oncol. 2023 Mar 2:109595. doi: 10.1016/j.radonc.2023.109595.
     PubMed     Abstract available
     
     
     
112. WANG JH, Salama V, McCoy L, Dede C, et al
     Dysphagia and shortness-of-breath as markers for treatment failure and survival in oropharyngeal cancer after radiation.
     Radiother Oncol. 2023;180:109465.
     PubMed     Abstract available
     
     
     February 2023
113. TAN W, Mao M, He H, Chen M, et al
     Endonasopharyngeal Ultrasound and Magnetic Resonance Imaging Features of Recurrent Retropharyngeal Nodes in Nasopharyngeal Carcinoma Patients: A Radiologic-histopathologic Study.
     Radiother Oncol. 2023 Feb 24:109579. doi: 10.1016/j.radonc.2023.109579.
     PubMed     Abstract available
     
     
     
114. BOLLEN H, Willems S, Wegge M, Maes F, et al
     Benefits of automated gross tumor volume segmentation in head and neck cancer using multi-modality information.
     Radiother Oncol. 2023 Feb 21:109574. doi: 10.1016/j.radonc.2023.109574.
     PubMed     Abstract available
     
     
     
115. ZHANG J, Lam SK, Teng X, Ma Z, et al
     Radiomic Feature Repeatability and Its Impact on Prognostic Model Generalizability: A Multi-Institutional Study on Nasopharyngeal Carcinoma Patients.
     Radiother Oncol. 2023 Feb 21:109578. doi: 10.1016/j.radonc.2023.109578.
     PubMed     Abstract available
     
     
     
116. VALENTINI C, Ebert N, Koi L, Pfeifer M, et al
     Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
     Radiother Oncol. 2023 Feb 20:109546. doi: 10.1016/j.radonc.2023.109546.
     PubMed     Abstract available
     
     
     
117. BEYAN C, Beyan E
     The prognosis may not be determined with the use of some pre-treatment complete blood count values in patients with non-metastatic nasopharyngeal carcinoma.
     Radiother Oncol. 2023 Feb 9:109529. doi: 10.1016/j.radonc.2023.109529.
     PubMed    
     
     
     
118. MAO JR, Lan KQ, Liu SL, Liu C, et al
     In reply to the Letter to the Editor by Cengiz Beyan and Esin Beyan regarding ''Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?".
     Radiother Oncol. 2023 Feb 9:109530. doi: 10.1016/j.radonc.2023.109530.
     PubMed    
     
     
     
119. PATRICIA KAPLAN L, Ivalu Sander Holm A, Grau Eriksen J, Heijmen BJM, et al
     Patient anatomy-specific trade-offs between sub-clinical disease coverage and normal tissue dose reduction in head-and-neck cancer.
     Radiother Oncol. 2023 Feb 8:109526. doi: 10.1016/j.radonc.2023.109526.
     PubMed     Abstract available
     
     
     
120. GEHIN W, Lassalle B, Salleron J, Anxionnat R, et al
     DOSIMETRIC PREDICTIVE FACTORS FOR FACIAL NERVE PARALYSIS AFTER CYBERKNIFE(R) STEREOTACTIC RADIOTHERAPY FOR VESTIBULAR SCHWANNOMAS: A SINGLE INSTITUTION EXPERIENCE OF 88 PATIENTS.
     Radiother Oncol. 2023 Feb 1:109519. doi: 10.1016/j.radonc.2023.109519.
     PubMed     Abstract available
     
     
     January 2023
121. YAO JJ, Jin YN, Zhang WJ, Zhang HY, et al
     Response to the letter by Dr Sari regarding the article "The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy".
     Radiother Oncol. 2023 Jan 31:109487. doi: 10.1016/j.radonc.2023.109487.
     PubMed    
     
     
     
122. TERZIDIS E, Friborg J, Vogelius I, Lelkaitis G, et al
     Tumor volume definitions in head and neck squamous cell carcinoma - comparing PET/MRI and histopathology.
     Radiother Oncol. 2023 Jan 20:109484. doi: 10.1016/j.radonc.2023.109484.
     PubMed     Abstract available
     
     
     
123. YE X, Liu J, Quan R, Lu Y, et al
     DKK1 Affects Survival of Patients with Head and Neck Squamous Cell Carcinoma by Inducing Resistance to Radiotherapy and Immunotherapy.
     Radiother Oncol. 2023 Jan 20:109485. doi: 10.1016/j.radonc.2023.109485.
     PubMed     Abstract available
     
     
     
124. LUO X, Liao W, He Y, Tang F, et al
     Deep learning-based accurate delineation of primary gross tumor volume of nasopharyngeal carcinoma on heterogeneous magnetic resonance imaging: a large-scale and multi-center study.
     Radiother Oncol. 2023 Jan 16:109480. doi: 10.1016/j.radonc.2023.109480.
     PubMed     Abstract available
     
     
     
125. WANG X, Bai H, Li R, Wang L, et al
     High versus Standard Radiation Dose of Definitive Concurrent Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
     Radiother Oncol. 2023 Jan 12:109463. doi: 10.1016/j.radonc.2023.109463.
     PubMed     Abstract available
     
     
     
126. LI Y, Sijtsema NM, de Vette SPM, Steenbakkers RJHM, et al
     Validation of the (18)F-FDG PET image biomarker model predicting late xerostomia after head and neck cancer radiotherapy.
     Radiother Oncol. 2023 Jan 3:109458. doi: 10.1016/j.radonc.2022.109458.
     PubMed     Abstract available
     
     
     
127. GUEVORGUIAN P, Chinnery T, Lang P, Nichols A, et al
     External validation of a CT-based radiomics signature in oropharyngeal cancer: Assessing sources of variation.
     Radiother Oncol. 2023;178:109434.
     PubMed     Abstract available
     
     
     December 2022
128. LEEUWENBERG AM, Reitsma JB, Bosch LVD, Hoogland J, et al
     The relation between prediction model performance measures and patient selection outcomes for proton therapy in head and neck cancer.
     Radiother Oncol. 2022 Dec 22:109449. doi: 10.1016/j.radonc.2022.109449.
     PubMed     Abstract available
     
     
     
129. HUANG X, Zhuang M, Yang S, Wang Y, et al
     The valuable role of dynamic (18)F FDG PET/CT-derived kinetic parameter K(i) in patients with nasopharyngeal carcinoma prior to radiotherapy: a prospective study.
     Radiother Oncol. 2022 Dec 22:109440. doi: 10.1016/j.radonc.2022.109440.
     PubMed     Abstract available
     
     
     
130. MAO JR, Lan KQ, Liu SL, Liu C, et al
     Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?
     Radiother Oncol. 2022 Dec 22:109445. doi: 10.1016/j.radonc.2022.109445.
     PubMed     Abstract available
     
     
     
131. LIU Y, Zhang Y, Wang J, Huang X, et al
     Caudal distribution pattern of metastatic neck lymph nodes in nasopharyngeal carcinoma and prognostic significance of nodal spread distances.
     Radiother Oncol. 2022 Dec 19:109443. doi: 10.1016/j.radonc.2022.109443.
     PubMed     Abstract available
     
     
     
132. ZHU GL, Zhang XM, Yang KB, Tang LL, et al
     Metastatic patterns of level II-V cervical lymph nodes assessed per vertebral levels in nasopharyngeal carcinoma.
     Radiother Oncol. 2022 Dec 19:109447. doi: 10.1016/j.radonc.2022.109447.
     PubMed     Abstract available
     
     
     
133. ZENG GP, Sun R, Zhao Z
     Letter to the editor regarding "The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: Significant acute and late toxicity reduction".
     Radiother Oncol. 2022 Dec 14:109442. doi: 10.1016/j.radonc.2022.109442.
     PubMed    
     
     
     
134. HU YJ, Lu TZ, Guo QJ, Zhang L, et al
     The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2N1 nasopharyngeal carcinoma: a multicenter retrospective study.
     Radiother Oncol. 2022 Dec 1:S0167-8140(22)04582.
     PubMed     Abstract available
     
     
     
135. DE FELICE F, Cirillo A, Botticelli A
     Ideal regimen for induction chemotherapy in nasopharyngeal cancer: Still a hot issue?
     Radiother Oncol. 2022;177:111-112.
     PubMed    
     
     
     November 2022
136. CHEN WY, Lu SH, Wang YM, Wang CW, et al
     Post-irradiation Sarcoma after Definitive Radiation Therapy for Nasopharyngeal Carcinoma.
     Radiother Oncol. 2022 Nov 23:S0167-8140(22)04560.
     PubMed     Abstract available
     
     
     
137. LIU ZC, Zeng KH, Gu ZB, Chen RP, et al
     Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching.
     Radiother Oncol. 2022 Nov 18:S0167-8140(22)04554.
     PubMed     Abstract available
     
     
     
138. WANG G, Huang C, Yang K, Guo R, et al
     Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
     Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04548.
     PubMed     Abstract available
     
     
     
139. YAO JJ, Jin YN, Lin YJ, Zhang WJ, et al
     The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy.
     Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04547.
     PubMed     Abstract available
     
     
     
140. BIN Y, Meng Z, Huang LL, Hu XY, et al
     Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.
     Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04549.
     PubMed     Abstract available
     
     
     
141. TAKADA A, Ichikawa Y, Nakamura S, Toyomasu Y, et al
     Preliminary results of reduced myocardial blood flow in the subacute phase after radiation therapy for thoracic esophageal cancer: A quantitative analysis with stress dynamic myocardial computed tomography perfusion imaging.
     Radiother Oncol. 2022 Nov 10. pii: S0167-8140(22)04546.
     PubMed    
     
     
     
142. ZHONG Z, Wang D, Liu Y, Shao S, et al
     Lymph Drainage and Cervical Fascia Anatomy-Oriented Differential Nodal CTV Delineation at the Supraclavicular Region for Esophageal Cancer and Nasopharyngeal Cancer.
     Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04531.
     PubMed    
     
     
     
143. CHOW JCH, Lui JCF, Cheung KM, Tam AHP, et al
     Post-radiation primary hypothyroidism in patients with head and neck cancer: External validation of thyroid gland dose-volume constraints with long-term endocrine outcomes.
     Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04529.
     PubMed     Abstract available
     
     
     
144. HUANG H, Miao J, Zhao C, Wang L, et al
     Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing inten
     Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04517.
     PubMed    
     
     
     
145. SARODE GS, Sarode SC, Anand R
     Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective pha
     Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04515.
     PubMed    
     
     
     
146. LEE CT, Litwin S, Yao CMKL, Liu JC, et al
     Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints.
     Radiother Oncol. 2022;176:215-221.
     PubMed     Abstract available
     
     
     
147. VAN DER WEIJST L, Azria D, Berkovic P, Boisselier P, et al
     The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
     Radiother Oncol. 2022;176:127-137.
     PubMed     Abstract available
     
     
     October 2022
148. ROESCH J, Oertel M, Wegen S, Trommer M, et al
     Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
     Radiother Oncol. 2022 Oct 20. pii: S0167-8140(22)04502.
     PubMed     Abstract available
     
     
     
149. TIEN CT, Chen CN, Young YH
     Post-irradiation endolymphatic hydrops vs. post-irradiation sudden deafness.
     Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04504.
     PubMed     Abstract available
     
     
     
150. RONN HANSEN C, Price G, Field M, Sarup N, et al
     Larynx cancer survival model developed through open-source federated learning.
     Radiother Oncol. 2022 Oct 5. pii: S0167-8140(22)04493.
     PubMed     Abstract available
     
     
     September 2022
151. NADERI E, Schack LMH, Welsh C, Sim AYL, et al
     Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer.
     Radiother Oncol. 2022 Sep 30. pii: S0167-8140(22)04486.
     PubMed     Abstract available
     
     
     
152. HUMBERT-VIDAN L, Hansen CR, Fuller CD, Petit S, et al
     Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for Mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN).
     Radiother Oncol. 2022 Sep 27. pii: S0167-8140(22)04473.
     PubMed    
     
     
     
153. DRAGUET C, Barragan-Montero AM, Chocan Vera M, Thomas M, et al
     Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancer.
     Radiother Oncol. 2022 Sep 24. pii: S0167-8140(22)04263.
     PubMed     Abstract available
     
     
     
154. OUD M, Breedveld S, Gizynska M, Kroesen M, et al
     An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer.
     Radiother Oncol. 2022 Sep 20. pii: S0167-8140(22)04278.
     PubMed     Abstract available
     
     
     August 2022
155. DE ROEST RH, van der Heijden M, W R Wesseling F, de Ruiter EJ, et al
     Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
     Radiother Oncol. 2022 Aug 13. pii: S0167-8140(22)04234.
     PubMed     Abstract available
     
     
     
156. ZHANG Y, Alshaikhi J, Amos RA, Lowe M, et al
     Improving workflow for adaptive proton therapy with predictive anatomical modelling: A proof of concept.
     Radiother Oncol. 2022;173:93-101.
     PubMed     Abstract available
     
     
     July 2022
157. GHATASHEH H, Hui Huang S, Su J, Xu W, et al
     Evaluation of risk-tailored individualized selection of radiation therapy target volume for Head and Neck Carcinoma of Unknown Primary.
     Radiother Oncol. 2022 Jul 26. pii: S0167-8140(22)04214.
     PubMed     Abstract available
     
     
     
158. HABRICH J, Boeke S, Nachbar M, Nikolaou K, et al
     Repeatability of diffusion-weighted magnetic resonance imaging in head and neck cancer at a 1.5 T MR-Linac.
     Radiother Oncol. 2022 Jul 25. pii: S0167-8140(22)04218.
     PubMed     Abstract available
     
     
     
159. HUANG H, Miao J, Xiao X, Hu J, et al
     Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): a prospective phase II randomized controlled study.
     Radiother Oncol. 2022 Jul 8. pii: S0167-8140(22)04191.
     PubMed     Abstract available
     
     
     
160. PRICE JM, West CM, Dixon LM, Iyizoba-Ebozue Z, et al
     Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharyngeal cancer: A multi-centre study.
     Radiother Oncol. 2022;172:111-117.
     PubMed     Abstract available
     
     
     June 2022
161. QIAN D, Chen X, Shang X, Wang Y, et al
     Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II rando
     Radiother Oncol. 2022 Jun 25. pii: S0167-8140(22)04176.
     PubMed     Abstract available
     
     
     
162. KROESE TE, Christ SM, van Rossum PSN, Burger MDL, et al
     Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study.
     Radiother Oncol. 2022 Jun 23. pii: S0167-8140(22)04173.
     PubMed     Abstract available
     
     
     
163. GONG J, Zhang W, Huang W, Liao Y, et al
     CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: a multicenter study.
     Radiother Oncol. 2022 Jun 21. pii: S0167-8140(22)04171.
     PubMed     Abstract available
     
     
     
164. HANSEN CR, Price G, Field M, Sarup N, et al
     Open-source distributed learning validation for a larynx cancer survival model following radiotherapy.
     Radiother Oncol. 2022 Jun 20. pii: S0167-8140(22)04170.
     PubMed     Abstract available
     
     
     
165. FU G, Xie Y, Pan J, Qiu Y, et al
     Longitudinal study of irradiation-induced brain functional network alterations in patients with nasopharyngeal carcinoma.
     Radiother Oncol. 2022 Jun 16. pii: S0167-8140(22)04164.
     PubMed     Abstract available
     
     
     
166. SCHOONBEEK RC, Festen S, van der Laan BFAM, Plaat BEC, et al
     The effect of delayed treatment initiation on adverse events and recurrence in older head and neck cancer patients.
     Radiother Oncol. 2022 Jun 6. pii: S0167-8140(22)04146.
     PubMed     Abstract available
     
     
     
167. MASSACCESI M, Dinapoli N, Fuga V, Rupe C, et al
     A predictive nomogram for trismus after radiotherapy for head and neck cancer.
     Radiother Oncol. 2022 Jun 2. pii: S0167-8140(22)04137.
     PubMed     Abstract available
     
     
     May 2022
168. LIU Z, Luo Y, Guo R, Yang B, et al
     Head and Neck Radiotherapy Causes Significant Disruptions of Cochlear Ribbon Synapses and Consequent Sensorineural Hearing Loss.
     Radiother Oncol. 2022 May 28. pii: S0167-8140(22)02279.
     PubMed     Abstract available
     
     
     
169. ZHAO DW, Fan WJ, Fang XM, Luo YR, et al
     Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
     Radiother Oncol. 2022 May 15. pii: S0167-8140(22)00251.
     PubMed     Abstract available
     
     
     
170. YI-LIANG SHEN E, Hung TM, Tsan DL, Cheng NM, et al
     Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating epstein-barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
     Radiother Oncol. 2022 May 11. pii: S0167-8140(22)00240.
     PubMed     Abstract available
     
     
     April 2022
171. ZHAO Y, Liao X, Wang Y, Lan W, et al
     Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy.
     Radiother Oncol. 2022 Apr 29. pii: S0167-8140(22)00232.
     PubMed     Abstract available
     
     
     
172. DOHOPOLSKI M, Wang K, Morgan H, Sher D, et al
     Predicting the need for aggressive nutritional supplementation in head and neck cancer patients receiving radiation therapy.
     Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00224.
     PubMed     Abstract available
     
     
     
173. SHEN H, Yin J, Niu R, Lian Y, et al
     Development and validation of a radiomic nomogram to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carc
     Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00222.
     PubMed     Abstract available
     
     
     
174. LEE BM, Lee CG
     Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer.
     Radiother Oncol. 2022 Apr 18. pii: S0167-8140(22)00191.
     PubMed     Abstract available
     
     
     
175. WELZ S, Paulsen F, Pfannenberg C, Reimold M, et al
     Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [(18)F]FMISO PET/CT.
     Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00170.
     PubMed     Abstract available
     
     
     
176. JENSEN KH, Vogelius IR, Bernsdorf M, Gothelf A, et al
     Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.
     Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00169.
     PubMed     Abstract available
     
     
     
177. LUDWIG R, Hoffmann JM, Pouymayou B, Dappen MB, et al
     Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface.
     Radiother Oncol. 2022;169:1-7.
     PubMed     Abstract available
     
     
     March 2022
178. YUE M, Xue X, Wang Z, Lambo RL, et al
     Dose prediction via distance-guided deep learning: initial development for nasopharyngeal carcinoma radiotherapy.
     Radiother Oncol. 2022 Mar 26. pii: S0167-8140(22)00150.
     PubMed     Abstract available
     
     
     
179. BORDERIAS-VILLARROEL E, Taasti V, Van Elmpt W, Teruel-Rivas S, et al
     Evaluation of the clinical value of automatic online dose restoration for adaptive proton therapy of head and neck cancer.
     Radiother Oncol. 2022 Mar 25. pii: S0167-8140(22)00149.
     PubMed     Abstract available
     
     
     
180. KARAVOLIA E, van Rijn-Dekker MI, Van den Bosch L, van den Hoek JGM, et al
     Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients.
     Radiother Oncol. 2022 Mar 15. pii: S0167-8140(22)00145.
     PubMed     Abstract available
     
     
     
181. ZHOU X, Wang W, Zhou C, Zhu J, et al
     Long-term outcomes of replanning during intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: An updated and expanded retrospective analysis.
     Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00132.
     PubMed     Abstract available
     
     
     
182. HUANG CC, Lai YR, Chiu WC, Fang FM, et al
     Concurrent chemoradiation therapy is associated with an accelerated risk of cardiovascular autonomic dysfunction in patients with nasopharyngeal carcinoma: A 9-year prospective follow-up study.
     Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00129.
     PubMed     Abstract available
     
     
     
183. CHOW R, Simone CB 2nd
     Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality.
     Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00112.
     PubMed    
     
     
     
184. DAI D, Tian Q, Shui Y, Li J, et al
     Response to "Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality".
     Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00109.
     PubMed    
     
     
     
185. NACHANKAR A, Musha A, Kubo N, Kawamura H, et al
     Dosimetric analysis of intraocular hemorrhage in nonsquamous head and neck cancers treated with carbon-ion radiotherapy.
     Radiother Oncol. 2022 Mar 4. pii: S0167-8140(22)00118.
     PubMed     Abstract available
     
     
     
186. GORPHE P, Classe M, Ammari S, Garcia G, et al
     Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma.
     Radiother Oncol. 2022;168:40-45.
     PubMed     Abstract available
     
     
     February 2022
187. LASKAR SG, Sinha S, Pai DP, Nair D, et al
     Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes.
     Radiother Oncol. 2022 Feb 24. pii: S0167-8140(22)00106.
     PubMed     Abstract available
     
     
     
188. BONOMO P, Desideri I, Mangoni M, Saieva C, et al
     Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial.
     Radiother Oncol. 2022 Feb 11. pii: S0167-8140(22)00091.
     PubMed     Abstract available
     
     
     
189. SCANDURRA D, Meijer TWH, Free J, van den Hoek JGM, et al
     Evaluation of robustly optimised intensity modulated proton therapy for nasopharyngeal carcinoma.
     Radiother Oncol. 2022 Feb 5. pii: S0167-8140(22)00080.
     PubMed     Abstract available
     
     
     
190. PAN D, Rong X, Zhu Y, Ng WT, et al
     A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis.
     Radiother Oncol. 2022 Feb 1. pii: S0167-8140(22)00060.
     PubMed     Abstract available
     
     
     January 2022
191. SUN XS, Zhu MY, Wen DX, Luo DH, et al
     Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in local recurrence nasopharyngeal carcinoma patients.
     Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00028.
     PubMed     Abstract available
     
     
     
192. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
     Head and neck cancer diagnoses and faster treatment initiation during COVID-19: correspondence.
     Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00026.
     PubMed    
     
     
     
193. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
     Response to "Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence".
     Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00033.
     PubMed    
     
     
     
194. CHATTERJEE S, Maulik S, Prasath S, Arun B, et al
     Xerostomia quality of life and resource requirements following parotid sparing adaptive radiotherapy in head and neck cancers: Results of a prospective cohort study (Study ID CTRI/2017/11/010683).
     Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00024.
     PubMed     Abstract available
     
     
     
195. ZECH HB, Berger J, Mansour WY, Nordquist L, et al
     Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.
     Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00022.
     PubMed     Abstract available
     
     
     
196. AL-MAMGANI A, Kessels R, Janssen T, Navran A, et al
     The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: significant acute and late toxicity reduction.
     Radiother Oncol. 2022 Jan 20. pii: S0167-8140(22)00017.
     PubMed     Abstract available
     
     
     
197. HE J, Qian L, Gao J
     Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
     Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00005.
     PubMed    
     
     
     
198. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
     Response to the Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)"by He et al.
     Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00006.
     PubMed    
     
     
     
199. DAI D, Tian Q, Shui Y, Li J, et al
     The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis.
     Radiother Oncol. 2022 Jan 8. pii: S0167-8140(22)00007.
     PubMed     Abstract available
     
     
     
200. HUANG W, Zhang Q, Wu G, Chen P, et al
     Corrigendum to "DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients" [Radiother Oncol (2021) 164:146-154].
     Radiother Oncol. 2022 Jan 7. pii: S0167-8140(21)09059.
     PubMed    
     
     
     
201. LIU T, Shen BW, Liu LT, Yang ZC, et al
     Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model.
     Radiother Oncol. 2022 Jan 5. pii: S0167-8140(21)09094.
     PubMed     Abstract available
     
     
     
202. FORNER LE, Dieleman FJ, Shaw RJ, Kanatas A, et al
     Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1.
     Radiother Oncol. 2022;166:137-144.
     PubMed     Abstract available
     
     
     December 2021
203. GUO Q, Xiao N, Xu H, Zong J, et al
     Rationality of the international guideline's recommendation regarding selective coverage of level Ib in clinical target volume with nasopharyngeal carcinoma: Results from a real-world series.
     Radiother Oncol. 2021 Dec 29. pii: S0167-8140(21)09081.
     PubMed     Abstract available
     
     
     
204. TANG SQ, Chen L, Li WF, Chan ATC, et al
     Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9,468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
     Radiother Oncol. 2021 Dec 28. pii: S0167-8140(21)09077.
     PubMed     Abstract available
     
     
     
205. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
     Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: a nationwide population-based analysis.
     Radiother Oncol. 2021 Dec 13. pii: S0167-8140(21)09049.
     PubMed     Abstract available
     
     
     
206. MUSHA A, Hirai C, Kitada Y, Tsunoda A, et al
     Relationship between oral mucositis and the oral bacterial count in patients with head and neck cancer undergoing carbon ion radiotherapy: A prospective study.
     Radiother Oncol. 2021 Dec 10. pii: S0167-8140(21)09054.
     PubMed     Abstract available
     
     
     
207. BEUKEMA JC, de Groot C, Plukker JTM, Vliegenthart R, et al
     Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study.
     Radiother Oncol. 2021 Dec 2. pii: S0167-8140(21)09025.
     PubMed     Abstract available
     
     
     November 2021
208. KUTZ LM, Abel J, Schweizer D, Tribius S, et al
     Quality of life, HPV-status and phase angle predict survival in head and neck cancer patients under (chemo)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial.
     Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09004.
     PubMed     Abstract available
     
     
     
209. JIN YN, Yang QQ, Li ZQ, Ou XQ, et al
     Development of a Web-based Prognostic Model to Quantify the Survival Benefit of Cumulative Cisplatin Dose during Concurrent Chemoradiotherapy in Childhood Nasopharyngeal Carcinoma.
     Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09008.
     PubMed     Abstract available
     
     
     
210. NISHIBUCHI I, Murakami Y, Kubo K, Imano N, et al
     Temporal Changes and Risk Factors for Esophageal Stenosis after Salvage Radiotherapy in Superficial Esophageal Cancer following Non-Curative Endoscopic Submucosal Dissection.
     Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09007.
     PubMed     Abstract available
     
     
     
211. PATEL V, Kwok J, Burke M, Urbano TG, et al
     Should the HPV positive oropharyngeal cancer patient be considered for a two-stage dental assessment for their radiation treatment?
     Radiother Oncol. 2021;164:232-235.
     PubMed     Abstract available
     
     
     
212. GAWRYSZUK A, Bijl HP, van der Schaaf A, Perdok N, et al
     Relationship between videofluoroscopic and subjective (physician- and patient- rated) assessment of late swallowing dysfunction after (chemo) radiation: Results of a prospective observational study.
     Radiother Oncol. 2021;164:253-260.
     PubMed     Abstract available
     
     
     October 2021
213. BROOKER RC, Antczak P, Liloglou T, Risk JM, et al
     Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy.
     Radiother Oncol. 2021;165:87-93.
     PubMed     Abstract available
     
     
     
214. CHIN O, Yu E, O'Sullivan B, Su J, et al
     Prognostic Importance of Radiologic Extranodal Extension in Nasopharyngeal Carcinoma Treated in a Canadian Cohort.
     Radiother Oncol. 2021 Oct 27. pii: S0167-8140(21)08785.
     PubMed     Abstract available
     
     
     
215. ZHANG ZM, Zhao R, Bao Y, Zhou LX, et al
     A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy.
     Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08758.
     PubMed     Abstract available
     
     
     
216. SHI Z, Zhu X, Ke S, Qiu H, et al
     Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses.
     Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08754.
     PubMed     Abstract available
     
     
     
217. YAN A, Hanna A, Wilson TG, Deraniyagala R, et al
     Correlation between tumor voxel dose response matrix and tumor biomarker profile in patients with head and neck squamous cell carcinoma.
     Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)08748.
     PubMed     Abstract available
     
     
     
218. KANEHIRA T, van Kranen S, Jansen T, Hamming-Vrieze O, et al
     Comparisons of normal tissue complication probability models derived from planned and delivered dose for head and neck cancer patients.
     Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)06738.
     PubMed     Abstract available
     
     
     September 2021
219. HUANG W, Zhang Q, Wu G, Pian Chen P, et al
     DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients.
     Radiother Oncol. 2021 Sep 27. pii: S0167-8140(21)06739.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Otorhinolaryngology is free of charge.